Within Household Transmission of COVID-19 Infections
VERDI
1 other identifier
observational
450
1 country
1
Brief Summary
In the absence of a vaccine, the spread of SARS-CoV-2 can only be mitigated via non-pharmaceutical interventions that reduce the risks of forward transmission. Currently, European policymakers are implementing combinations of fierce pandemic control measures. However, there is substantial uncertainty on the transmission dynamics of SARS-CoV-2 and, consequently, the effect of each specific mitigation intervention as well as their joint impact on the pandemic evolution. Moreover, it is uncertain how and when the Public Health response should be modified once the pandemic starts to slow. There is an urgent need for data that can help to further unravel the key transmission characteristics of SARS-CoV-2 in the population. Household studies are, therefore, a useful approach to obtain insight into the main determinants of transmission and to derive estimates of transmission parameters. By fully characterizing the critical process of SARS-CoV-2 household transmission and how they vary by patient and household characteristics, infection dynamics in the population can be further elucidated. Responding to SARS-CoV-2 effectively from a community care perspective will also require understanding the perceptions, beliefs, and actions taken by patients and the public. A 'bottom-up' understating of such issues is critical to understand how best to design effective community strategies. Rapid European COVID-19 Emergency Research response (RECOVER) is a project involving ten international partners that have been selected for funding by the European Union under the Horizon 2020 research framework. RECOVER responds to call topic SC1-PHE-CORONAVIRUS-2020: Advancing knowledge for the clinical and public health response to the SARS-CoV-2 epidemic and builds on many years of investment by the European Commission in clinical research preparedness for epidemic response. RECOVER will therefore provide a range of data and analytical results to guide the Public Health response, including the here described household transmission study. Objective: Estimate key transmission parameters of SARS-CoV-2 in Europe from observing within household virus spread and seroconversion of household members and characterize the views and experiences of households regarding perceptions, practices regarding infection control, and impacts of imposed isolation measures.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2022
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 15, 2022
CompletedFirst Submitted
Initial submission to the registry
March 17, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2022
CompletedFirst Posted
Study publicly available on registry
June 24, 2022
CompletedJune 24, 2022
June 1, 2022
4 months
March 17, 2022
June 23, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Estimate key transmission parameters of SARS-CoV-2 in Europe from observing within household virus spread and seroconversion of household members through study completion, an average of 4 weeks.
Estimate key transmission parameters of SARS-CoV-2 in Europe from observing within household virus spread and seroconversion of household members. Including secondary attack rates and Transmission rate.
Samples and data collected through study completion, an average of 4 weeks.
Secondary Outcomes (6)
Estimate the incubation period through study completion, an average of 4 weeks.
Samples and data collected through study completion, an average of 4 weeks.
Estimate the generation time through study completion, an average of 4 weeks.
Samples and data collected through study completion, an average of 4 weeks.
Estimate the susceptibility through study completion, an average of 4 weeks.
Samples and data collected through study completion, an average of 4 weeks.
Estimate the infectiousness through study completion, an average of 4 weeks.
Samples and data collected through study completion, an average of 4 weeks.
Estimate the transmission through study completion, an average of 4 weeks.
Samples and data collected through study completion, an average of 4 weeks.
- +1 more secondary outcomes
Study Arms (1)
Families
Patients with confirmed SARS-Cov-2 infection and their household members of all ages can be enrolled in the study, if at least one household member is a child age under 18.
Interventions
Eligibility Criteria
Communty within the region of Utrecht
You may qualify if:
- All members of the household or their legal guardians consent to participation
- All members of the household are willing to complete diaries and questionnaires for the duration of follow-up
You may not qualify if:
- Patients or household members who are unable to consent, or do not wish to provide informed consent.
- Children, pregnant women and patients lacking capacity will be included. Those lacking capacity to consent for themselves will be identified and consent will be sought from an appropriate consulted.
- Households who do not have daily access to a smartphone or tablet with internet connection, will be excluded, as follow-up of households requires the use of an interactive diary App.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- UMC Utrechtlead
Study Sites (1)
UMC Utrecht
Utrecht, 3584CX, Netherlands
Study Officials
- PRINCIPAL INVESTIGATOR
Patricia Bruijning, MD PhD
UMC Utrecht
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
March 17, 2022
First Posted
June 24, 2022
Study Start
January 15, 2022
Primary Completion
May 1, 2022
Study Completion
May 1, 2022
Last Updated
June 24, 2022
Record last verified: 2022-06